Steve Connor: Even if gene therapy does work, how will a stretched NHS foot the bill?
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Gene therapy is one of those medical "breakthroughs" that has unfortunately failed to live up to expectations. Several clinical trials, usually involving inherited diseases caused by defects in single genes, have ended in failure and, in at least one case, the death of patients.
For the past two decades, scientists have tried with varying degrees of success to insert, augment or in some way alter the damaged or missing genes that have caused a particular illness. This latest attempt is somewhat different, in that even a partial increase in gene function should result in a marked improvement in a patient's quality of life.
Even a 10 or 20 per cent improvement in the pumping efficiency of a failing heart, for instance, could allow a patient to climb the stairs without getting out of breath.
The two studies to start in Britain are part of "phase 2" clinical trials on a few dozen patients to primarily test safety, but also the efficacy of the treatment. It could take another two or three years before any meaningful results appear.
A further three or even five years are then necessary for the final, "phase 3" trials involving hundreds of patients. These should show beyond reasonable doubt whether the therapy really does significantly improve a patient's outlook.
But if gene therapy proves to work, the big question is whether the NHS will be able to afford yet another new treatment, costing several thousand pounds a shot.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments